Published in Support Care Cancer on April 29, 2009
Health effects of dietary phospholipids. Lipids Health Dis (2012) 1.21
Marine omega-3 phospholipids: metabolism and biological activities. Int J Mol Sci (2012) 1.12
Marine polyunsaturated fatty acids and cancer therapy. Br J Cancer (2013) 1.06
Effects of matrine on the proliferation of HT29 human colon cancer cells and its antitumor mechanism. Oncol Lett (2013) 0.88
A systematic review of health-related quality of life instruments in patients with cancer cachexia. Support Care Cancer (2013) 0.81
Dietary omega-3 polyunsaturated fatty acids alter the fatty acid composition of hepatic and plasma bioactive lipids in C57BL/6 mice: a lipidomic approach. PLoS One (2013) 0.79
Effects of Marine Phospholipids Extract on the Lipid Levels of Metastatic and Nonmetastatic Prostate Cancer Patients. Int Sch Res Notices (2014) 0.75
The challenge of appropriate identification and treatment of starvation, sarcopenia, and cachexia: a survey of Australian dietitians. J Nutr Metab (2011) 0.75
Dietary supplementation with n-3-fatty acids in patients with pancreatic cancer and cachexia: marine phospholipids versus fish oil - a randomized controlled double-blind trial. Lipids Health Dis (2017) 0.75
A rapid method of total lipid extraction and purification. Can J Biochem Physiol (1959) 173.74
The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst (1993) 38.99
Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol (1998) 9.89
Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med (1980) 6.12
The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med (1989) 5.02
Prostaglandins and cancer. Gut (2005) 3.44
Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg (1994) 2.69
Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr (2006) 2.66
Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study. J Clin Oncol (2003) 2.38
Pharmacologic therapy for the cancer anorexia/weight loss syndrome: A data-driven, practical approach. J Support Oncol (2006) 2.10
Cellular responses to excess phospholipid. J Biol Chem (1999) 1.99
Efficacy of dietary arachidonic acid provided as triglyceride or phospholipid as substrates for brain arachidonic acid accretion in baboon neonates. Pediatr Res (2002) 1.82
Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care (2005) 1.73
Measuring the symptom experience of seriously ill cancer and noncancer hospitalized patients near the end of life with the memorial symptom assessment scale. J Pain Symptom Manage (2003) 1.65
Inhibition of calcium-independent phospholipase A2 prevents arachidonic acid incorporation and phospholipid remodeling in P388D1 macrophages. Proc Natl Acad Sci U S A (1995) 1.61
Lipoxygenase metabolism: roles in tumor progression and survival. Cancer Metastasis Rev (2007) 1.57
Phase II study of high-dose fish oil capsules for patients with cancer-related cachexia. Cancer (2004) 1.56
The cancer cachexia syndrome: a review of metabolic and clinical manifestations. Nutr Clin Pract (2005) 1.55
The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. Br J Cancer (1999) 1.46
Eicosanoids in inflammation: biosynthesis, pharmacology, and therapeutic frontiers. Curr Top Med Chem (2007) 1.42
Lysophosphatidylcholine and 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine inhibit the CDP-choline pathway of phosphatidylcholine synthesis at the CTP:phosphocholine cytidylyltransferase step. J Biol Chem (1995) 1.33
Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol (2006) 1.23
Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6. Clin Sci (Lond) (1997) 1.15
The validity of bioelectrical impedance models in clinical populations. Nutr Clin Pract (2004) 1.15
Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: cancer and leukemia group B study 9473. Clin Cancer Res (1999) 1.11
Endothelial lipase releases saturated and unsaturated fatty acids of high density lipoprotein phosphatidylcholine. J Lipid Res (2005) 1.09
Evaluation of nutritional status in advanced metastatic cancer. Support Care Cancer (2003) 1.05
Role for 18:1 lysophosphatidic acid as an autocrine mediator in prostate cancer cells. J Biol Chem (2002) 1.04
Plasma lyso-phosphatidylcholine concentration is decreased in cancer patients with weight loss and activated inflammatory status. Lipids Health Dis (2007) 0.98
Intestinal absorption of polyenephosphatidylcholine in man. J Lipid Res (1982) 0.95
Tumor-host interactions. J Cell Biochem (2004) 0.94
31P NMR spectroscopy of blood plasma: determination and quantification of phospholipid classes in patients with renal cell carcinoma. NMR Biomed (2002) 0.93
Analysis of plasma lipids by NMR spectroscopy: application to modifications induced by malignant tumors. J Lipid Res (1993) 0.92
Systemic alterations in phospholipid concentrations of blood plasma in patients with thyroid carcinoma: an in-vitro (31)P high-resolution NMR study. NMR Biomed (2000) 0.90
Application of 31P NMR spectroscopy in clinical analysis of changes of serum phospholipids in leukemia, lymphoma and some other non-haematological cancers. Anticancer Res (1996) 0.89
A review of the drug treatment of cachexia associated with cancer. Drugs (1998) 0.88
Nutritional therapy for cancer cachexia. Gut (2003) 0.88
A clinical single-pass perfusion investigation of the dynamic in vivo secretory response to a dietary meal in human proximal small intestine. Pharm Res (2006) 0.87
Increased prostatic lysophosphatidylcholine acyltransferase activity in human prostate cancer: a marker for malignancy. J Urol (2001) 0.83
Impact of fish oil and melatonin on cachexia in patients with advanced gastrointestinal cancer: a randomized pilot study. Nutrition (2005) 0.83
Tumor necrosis factor-alpha induces the 85-kDa cytosolic phospholipase A2 gene expression in human bronchial epithelial cells. Biochim Biophys Acta (1996) 0.82
Investigating the utility of serum cytokine measurements in a multi-institutional cancer anorexia/weight loss trial. Support Care Cancer (2004) 0.80
n-3 and n-6 fatty acid enrichment by dietary fish oil and phospholipid sources in brain cortical areas and nonneural tissues of formula-fed piglets. Lipids (1999) 0.79
[Absorption of di-linoleoylphosphatidylcholine after oral administration]. Arzneimittelforschung (1995) 0.79
Interleukin-1beta-induced type IIA secreted phospholipase A2 gene expression and extracellular activity in rat vascular endothelial cells. Tissue Cell (2001) 0.78
Group II phospholipase A2 in invasive gastric cancer cell line is induced by interleukin 6. Biochem Biophys Res Commun (1994) 0.78
Metabolic alterations during inflammation and its modulation by central actions of omega-3 fatty acids. Curr Opin Clin Nutr Metab Care (2003) 0.78
Effects of omega-3 fatty acid supplementation on tumor-bearing rats. J Am Coll Surg (2004) 0.78
Fish oil, lean tissue, and cancer: is there a role for eicosapentaenoic acid in treating the cancer anorexia/weight loss syndrome? Crit Rev Oncol Hematol (2005) 0.75
Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol (2007) 4.00
A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res (2012) 2.78
Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol (2012) 2.45
The causes and consequences of cancer-associated malnutrition. Eur J Oncol Nurs (2005) 1.75
Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients--results of a phase II study. Onkologie (2007) 1.60
Phase II STUdy with 3rd- or 4th-line bendamustine (flat dose) therapy in patients with metastatic breast cancer. Onkologie (2009) 1.44
Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur J Cancer (2005) 1.42
Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res (2005) 1.33
Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res (2009) 1.32
Temporal expression of adhesion factors and activity of global regulators during establishment of Staphylococcus aureus nasal colonization. J Infect Dis (2010) 1.30
Health effects of dietary phospholipids. Lipids Health Dis (2012) 1.21
DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study. J Angiogenes Res (2009) 1.15
Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. Anticancer Res (2004) 1.09
Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study. Cancer Chemother Pharmacol (2004) 1.05
Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2. Breast Cancer Res Treat (2003) 1.05
A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Cancer Res (2003) 1.02
Plasma lyso-phosphatidylcholine concentration is decreased in cancer patients with weight loss and activated inflammatory status. Lipids Health Dis (2007) 0.98
Antimetastatic effects of liposomal gemcitabine and empty liposomes in an orthotopic mouse model of pancreatic cancer. Pancreas (2009) 0.96
Lysophosphatidylcholine pretreatment reduces VLA-4 and P-Selectin-mediated b16.f10 melanoma cell adhesion in vitro and inhibits metastasis-like lung invasion in vivo. Mol Cancer Ther (2011) 0.93
Characterization and comparison of 2 distinct epidemic community-associated methicillin-resistant Staphylococcus aureus clones of ST59 lineage. PLoS One (2013) 0.92
Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584. Semin Oncol (2003) 0.92
Antitumoral and antiangiogenic efficacy of bisphosphonates in vitro and in a murine RENCA model. Anticancer Res (2008) 0.92
Surveillance of siRNA integrity by FRET imaging. Nucleic Acids Res (2007) 0.90
Uptake of apolipoprotein E fragment coupled liposomes by cultured brain microvessel endothelial cells and intact brain capillaries. J Drug Target (2009) 0.89
Polyethylene glycol conjugates of methotrexate varying in their molecular weight from MW 750 to MW 40000: synthesis, characterization, and structure-activity relationships in vitro and in vivo. Bioconjug Chem (2002) 0.89
Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP). Int J Cancer (2008) 0.88
c-kit (CD117) expression in human tumors and its prognostic value: an immunohistochemical analysis. Pathol Oncol Res (2010) 0.87
Synthesis and in vitro efficacy of acid-sensitive poly(ethylene glycol) paclitaxel conjugates. Bioorg Med Chem Lett (2003) 0.86
Receptor tyrosine kinases: the main targets for new anticancer therapy. Curr Drug Targets (2003) 0.85
Tumour Biology: tumour-associated inflammation versus antitumor immunity. Anticancer Res (2009) 0.84
Correlation of the acid-sensitivity of polyethylene glycol daunorubicin conjugates with their in vitro antiproliferative activity. Bioorg Med Chem (2006) 0.84
Liposomal gemcitabine (GemLip)-efficient drug against hormone-refractory Du145 and PC-3 prostate cancer xenografts. Prostate (2009) 0.83
A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancer. Anticancer Res (2010) 0.83
Gemcitabine and interferon-alpha 2b in solid tumors: a phase I study in patients with advanced or metastatic non-small cell lung, ovarian, pancreatic or renal cancer. Anticancer Drugs (2002) 0.82
Anti-metastatic effects of liposomal gemcitabine in a human orthotopic LNCaP prostate cancer xenograft model. Clin Exp Metastasis (2009) 0.82
Development of a novel prodrug of paclitaxel that is cleaved by prostate-specific antigen: an in vitro and in vivo evaluation study. Eur J Cancer (2010) 0.80
IFN-y enhances T(H)1 polarisation of monocyte-derived dendritic cells matured with clinical-grade cytokines using serum-free conditions. Anticancer Res (2008) 0.79
On the mechanism of alkylphosphocholine (APC)-induced apoptosis in tumour cells. Biol Chem (2005) 0.79
Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen. Arch Pharm (Weinheim) (2005) 0.79
PAC fixed dose: pharmacokinetics of a 1-hour paclitaxel infusion and comparison to BSA-normalized drug dosing. Onkologie (2006) 0.78
FRET imaging of cells transfected with siRNA/liposome complexes. Methods Mol Biol (2010) 0.78
Comment on van den Berg et al: "methodology of clinical nutrition guidelines for adult cancer patients: how good are they according to AGREE criteria?". JPEN J Parenter Enteral Nutr (2012) 0.77
A fishy conclusion regarding n-3 fatty acid supplementation in cancer patients. Clin Nutr (2012) 0.77
Quantification of various phosphatidylcholines in liposomes by enzymatic assay. AAPS PharmSciTech (2003) 0.77
Lysophosphatidylcholine attenuates melanoma cell adhesion and migration dependent on the degree of fatty acid saturation. Int J Clin Pharmacol Ther (2015) 0.76
Combinatorial synthesis of new cationic lipids and high-throughput screening of their transfection properties. Chembiochem (2002) 0.75
Palliative treatment: anticancer, antisymptom, or end-of-life care? J Clin Oncol (2011) 0.75
[On: Michalsen A: Nutritional therapy: queen or Cinderella of naturopathy and complementary medicine? Forsch Komplementmed 2009;16:144-145 ]. Forsch Komplementmed (2009) 0.75
Metastasizing, Luciferase Transduced MAT‑Lu Rat Prostate Cancer Models: Follow up of Bolus and Metronomic Therapy with Doxorubicin as Model Drug. Cancers (Basel) (2011) 0.75
To live or not to live: parenteral nutrition in subjects with isolated gut failure. JPEN J Parenter Enteral Nutr (2010) 0.75
Click modification of multifunctional liposomes bearing hyperbranched polyether chains. Biomacromolecules (2014) 0.75
Pharmacokinetics and antitumor activity of vincristine entrapped in vesicular phospholipid gels. Anticancer Drugs (2002) 0.75
Inhibition of cytochrome P450 mediated enzyme activity by alkylphosphocholines. Z Naturforsch C (2005) 0.75
[Receptor tyrosine kinases. A target for new cancer treatments]. Med Monatsschr Pharm (2004) 0.75
[Nutrition in Cancer: Effective in Prevention and Treatment?] Dtsch Med Wochenschr (2017) 0.75
[Bisphosphonates in oncology]. Med Monatsschr Pharm (2003) 0.75
Treatment of anthracycline extravasation with dexrazoxane -- clinical experience. Onkologie (2006) 0.75
Quality of care for cancer patients on home parenteral nutrition: development of key interventions and outcome indicators using a two-round Delphi approach. Support Care Cancer (2012) 0.75
Cytotoxic efficacy and influence on cellular phospholipid metabolism of 2-hydroxy- and 2-O-acetyl-octadecylphosphocholines. Anticancer Res (2007) 0.75
Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthrapyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: a phase I study group trial of the Central European Society of Anticancer-Drug Research (CESAR). Anticancer Drugs (2004) 0.75
Preparation of small amounts of sterile siRNA-liposomes with high entrapping efficiency by dual asymmetric centrifugation (DAC). J Control Release (2008) 0.75